← Leaderboards
Christina U Lorentz
Aronora, Inc.
$5,989,807
Attributed
$11,979,614
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,979,614 · 5
By mechanism
R44$11,979,614 · 5
Top collaborators
- Erik Ian Tucker13 shared
Most similar at Aronora, Inc.
Same institution · by research overlap
- Erik Ian Tucker$22,365,229
- Michael Wallisch$1,130,711
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyDoseProduct DevelopmentMedicalHemorrhageBlood CoagulationSmall Business Innovation Research GrantPharmaceutical PreparationsToxic EffectDrug CandidatePrimatesClinical TrialsPreventBloodMortalityAnticoagulantsLifeAcuteInnovationChronicHemostatic AgentsHemodialysisDouble-Blind MethodFibrinolytic Agents
Grant awards (13)
Contact Pathway Inhibitor to Prevent Vascular Access Failure$1,331,056
R44 · FY2025 · HL · contact PI
Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$1,069,527
R44 · FY2025 · HL · contact PI
Contact Pathway Inhibitor to Prevent Vascular Access Failure$1,480,856
R44 · FY2024 · HL · contact PI
Thrombopoietin Targeting in Myeloproliferative Neoplasms$669,111
R44 · FY2024 · HL · contact PI
Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$493,999
R44 · FY2024 · HL · contact PI
Contact Pathway Inhibitor to Prevent Vascular Access Failure$998,549
R44 · FY2023 · HL · contact PI
Thrombopoietin Targeting in Myeloproliferative Neoplasms$700,302
R44 · FY2023 · HL · contact PI
Factor XII Inhibitor for Surface Initiated Thrombosis$953,492
R44 · FY2022 · HL
Thrombopoietin Targeting in Myeloproliferative Neoplasms$301,788
R44 · FY2022 · HL · contact PI
Factor XII Inhibitor for Surface Initiated Thrombosis$981,954
R44 · FY2021 · HL
Factor XII Inhibitor for Surface Initiated Thrombosis$999,930
R44 · FY2020 · HL
Factor XI inhibitor for thrombosis$999,525
R44 · FY2019 · HL
Factor XI inhibitor for thrombosis$999,525
R44 · FY2018 · HL